Table 1 Baseline ctDNA mutation prevalence and patient subsets.
Part 1: randomized GDC-0941 and placebo GDC-0941 patients | |||
|---|---|---|---|
| Â | ESR1 wild type, 96 (62.7%) | ESR1 mutation, 57 (37.3%) | Total, 153 (100%) |
ESR1 mutation number | |||
 0 | 96 (100%) | 0 | 96 (62.7%) |
 1 | 0 | 34 (59.6%) | 34 (22.2%) |
 2 | 0 | 13 (22.8%) | 13 (8.5%) |
 3+ | 0 | 10 (17.5%) | 10 (6.5%) |
PIK3CA status ctDNA | |||
 Wild type | 68 (70.8%) | 23 (40.4%) | 91 (59.5%) |
 Mutation | 28 (29.2%) | 34 (59.6%) | 62 (40.5%) |
Luminal status | |||
 Luminal A | 58 (60.4%) | 41 (71.9%) | 99 (64.7%) |
 Luminal B | 30 (31.3%) | 14 (24.6%) | 44 (28.8%) |
 Other | 8 (8.3%) | 2 (3.5%) | 10 (6.5%) |
Visceral disease | |||
 Yes | 45 (46.9%) | 35 (61.4%) | 80 (52.3%) |
 No | 51 (53.1%) | 22 (38.6%) | 73 (47.7%) |
Resistance to prior AI | |||
 Primary | 42 (43.8%) | 15 (26.3%) | 57 (37.3%) |
 Secondary | 54 (56.3%) | 41 (71.9%) | 95 (62.1%) |
 Unknown | 0 | 1 (1.8%) | 1 (0.7%) |
Number of metastatic sites | |||
 0 | 5 (5.2%) | 1 (1.8%) | 6 (3.9%) |
 1 | 37 (38.5%) | 13 (22.8%) | 50 (32.7%) |
 2+ | 54 (56.3%) | 43 (75.4%) | 97 (63.4%) |
| Â | PIK3CA wild type, 94 (60.3%) | PIK3CA mutation, 62 (39.7%) | Total, 156 (100%) |
PIK3CA mutation number | |||
 0 | 94 (100%) | 0 | 94 (60.3%) |
 1 | 0 | 56 (90.3%) | 56 (35.9%) |
 2+ | 0 | 6 (9.7%) | 6 (3.8%) |
Luminal status | |||
 Luminal A | 56 (59.6%) | 44 (71.0%) | 100 (64.1%) |
 Luminal B | 28 (29.8%) | 17 (27.4%) | 45 (28.8%) |
 Other | 10 (10.6%) | 1 (1.6%) | 11 (7.1%) |
